News

Madrigal Reports Third Quarter 2016 Financial Results

November 15, 2016
download

Madrigal Pharmaceuticals Announces the Initiation of a Phase 2 Study of MGL-3196 in Patients with Non-alcoholic Steatohepatitis (NASH)

October 20, 2016
download

Madrigal Pharmaceuticals and Tarveda Therapeutics Announce Exclusive License Agreement for HSP90 Drug Conjugate Oncology Platform

September 19, 2016
download

Richard S. Levy, MD, Appointed to Madrigal Board of Directors

August 11, 2016
download

Madrigal Pharmaceuticals Completes Merger with Synta to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

July 22, 2016
download

Synta and Madrigal Announce Merger Agreement to Create Leading Cardiovascular-Metabolic Diseases and NASH Company

April 14, 2016
download